Pharmaceutical Market: February 2015

Wednesday, 25 February 2015

Smoking Cessation and Nicotine De-addiction Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Smoking Cessation and Nicotine De-addiction Products Market Estimated to Value USD 16.02 Billion Globally by 2019
According to the report "Smoking Cessation and Nicotine De-addiction Products Market (Nicotine Gums, Patches, Lozenges, Inhalers, Sprays, Sublingual Tablets, Zyban, Chantix/Champix, E-cigarettes) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" ,the global market for Smoking Cessation and Nicotine De-addiction Products is estimated to grow at the rate of CAGR 8.7% in the forecasted period of 2013 to 2019 and reach a value of USD 16.02billion in 2019. This market was valued at USD 5.1 billion in 2012.

Browse the full report at
http://www.transparencymarketresearch.com/smoking-cessation-nicotine-de-addiction-products.html

Smoking is a global epidemic and is rapidly penetrating the world at strikingly high rates. It is estimated that there are roughly 1.1 to 1.3 billion tobacco users in the world, a figure that is likely to rise to 1.6 billion over the next two decades.
Tobacco smoke contains over 4000 chemicals of which 250 are known to be fatally harmful to humans. At least one person dies every 6 seconds from a tobacco related disease, which means, at least 10 people per minute die of a disease acquired due to use of tobacco in the world.

Smoking cessation is the medical terminology for a way to quit smoking through the use of various medicines. This may also involve assistance from healthcare professionals, psychotherapy and counseling. Knowing the risks associated with this addiction, many healthcare organizations as well as the people who wish to quit smoking are continuously adding to the demand for smoking cessation products, which include e-cigarettes, drug therapy and nicotine replacement therapy (NRT) products.

Products-wise Segmentation:
Among these three major segments of the Smoking cessation industry the NRT products, which directly transport nicotine into the users bloodstream by the virtue of flavored inhalers, mouth sprays, nicotine gums, patches, tablets and lozenges, are quite popular. Nicotine gums, especially, had a market value of USD 995.5 million in 2012. Nicotine patches and lozenges are also used quite often used in smoking cessation therapies as these are commonly available without the need of a physician’s prescription. Nicotine sprays and inhalers, on the other hand, are less popular due to their high cost. The major players in the NRT product market include Cipla, Novartis, Johnson and Johnson and Glaxo Smith Klien(GSK).

We are currently offering a flat 15% discount on all purchases until end of the March 2015!
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1849

By the end of the forecast period, the report estimates that the drug-therapy market of smoking cessation is estimated to witness a downfall resulting from license expiration of key drugs in the current market including - Zyban (bupropion) that has already lost its license in 2013 and Chantix/Champix (varenicline) that will have its license expired in 2018. The leading manufacturers in this segment are Pfizer and
GSK.

In the forecast period, the segment of e-cigarettes is expected to show the highest and fastest growth in the smoking cessation and nicotine de-addiction products market. The popularity of such cigarettes is high amongst young population and it is estimated that this popularity can pose challenge to other smoking cessation products in the market. The market value of this segment was estimated to be USD 1,662.5 million in 2012. The major players in this industry include VMR products LLC, NJOY and Lorillard.

Geography-wise Segmentation:
Geographically, North America was found to be the market leader of the global smoking cessation and nicotine de-addiction products market in 2012. This was followed by the European market, which stood at the second position in market share holdings. . The North American market was valued at USD 1,958.8 million in the year 2012.

Download PDF: Smoking Cessation and Nicotine De-addiction Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

About us:
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Browse The Market Research Blog :
https://marketsresearchindustry.wordpress.com/

Tuesday, 24 February 2015

Human Reproductive Technologies Market - Market Dynamics and Opportunities Report by Transparency Market Research

Human Reproductive Technologies Market - Global Industry Analysis, Size, Procedures, Growth, Trends and Forecast, 2013 - 2019
In the new report published by Transparency Market Research “Human Reproductive Technologies Market - Global Industry Analysis, Size, Procedures, Growth, Trends and Forecast, 2013 - 2019,” the global human reproductive market technologies was worth US$23.0 billion in 2012. However, according to some recent research and statistics the overall human reproductive technologies market is growing at a CAGR 2.2% from 2013 to 2019 and is expected to reach US$27.1 billion in 2019.

Browse the full report at
http://www.transparencymarketresearch.com/human-reproductive-technologies-market.html

In order to provide a thorough analysis of the overall competitive scenario in the global human reproductive technologies market, this report covers every aspect of the market and analyzes it in terms of treatment technologies, drugs, and various devices that are used to assist and control human reproduction.
Considering the human reproductive technologies market on the basis of market segmentation, the global market is divided into two major segments: contraceptive technologies and infertility treatments. The report involves the study of several providers and manufacturers of contraceptive technologies and infertility solutions too.

The contraceptive technologies market is further classified into contraceptive devices and drugs. The contraceptive devices market is sectioned into female contraceptive devices and male contraceptive devices (condoms), while, the contraceptive drugs market comprises topical contraceptives, contraceptive injectables, and oral contraceptive pills.
In 2012, the global contraceptives market was worth US$16.0 billion; however, presently, the market is expected to grow at a CAGR of 5.5% from 2013 to 2019. Among the varied contraceptive drugs, the oral contraceptive pills market held the highest revenue in 2012 and thus, led the overall contraceptives market in the same year. The growth was also mainly due to rising awareness about oral contraceptive pills among population through advertisements. People can buy drugs over-the-counter as well.

At the same time, the contraceptive devices market - male condoms was considered to be the largest market segment due to awareness among population and increased accessibility with ease of use.

We are currently offering a flat 15% discount on all purchases until end of the March 2015!
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1876

Likewise, the report also provides details about the infertility technologies market which is broadly analyzed with respect to types of treatment procedures and drugs. The types of infertility treatment methods studied in the report include zygote intrafallopian transfer (ZIFT), intrauterine insemination (IUI), intracytoplasmic sperm injection (ICSI), in vitro fertilization (IVF), and gamete intrafallopian transfer (GIFT). Furthermore, with respect to infertility drugs, the market witnesses three primary classes involving certain leading brands (by sales), namely, androgens, gonadotropins, and erectile dysfunction. Some of the other drugs analyzed in this study report include AndroGel, Viagra, Gonal-f, Cialis, Follistim AQ, Testim, and Levitra/Staxyn.
Among all the aforementioned drugs, Viagra was the largest drug brand (by revenue) in 2012 and has been a renowned and approved brand by the U.S. FDA, since 1998. Owing to increasing incidences of erectile dysfunction in male infertility, Viagra is still at a commanding position in the global infertility market. Moreover, for testosterone deficiency, AndroGel is the most preferred drug for the treatment, and Gonal-f under the gonadotropin class is a widely prescribed brand to achieve better results for infertility issues.

The report study observes some of the main players in the global human reproductive technologies market which include Merck Serono, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Abbott Laboratories, Bayer AG, Watson Pharmaceuticals, Pfizer, Inc., and Reckitt Benckiser. Generic manufacturers such as Par Pharmaceuticals and Watson Pharmaceuticals are expected to penetrate the global human reproductive technologies market with their new generic versions by 2015.

North America was a dominant player in the global human reproductive technologies market in 2012 and this region is further expected to maintain its market position till 2019. Nevertheless, the Asia-Pacific contraceptive technologies market is also growing rapidly mainly due to the rising awareness and acceptance of human reproductive technologies in this region. The growth rate is estimated to be 6.9% CAGR from 2013 to 2019.

Download PDF: Human Reproductive Technologies Market - Global Industry Analysis, Size, Procedures, Growth, Trends and Forecast, 2013 - 2019

Browse The Market Research Blog :
https://marketsresearchindustry.wordpress.com/

Meningococcal Vaccines Market - Market Dynamics and Opportunities Report by Transparency Market Research

Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
Transparency Market Research, a U.S. based market intelligence firm has added the report, titled “Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019”, to its research reports repository. The report states that the global meningococcal vaccines market has the potential of growing at a CAGR of 14.9% during 2013 and 2019. Growing at this pace, this market that valued US$1.5 billion in 2012 could achieve a net worth of US$3.7 billion by 2019.

Browse the full report at
http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html

Various strains of meningococcal bacteria cause serious infection to the thin lining surrounding the brain and spinal cord. The infection results in severe brain damage and can be fatal in 50% cases if left untreated. The high fatality rate of meningococcal disease is generally considered as a medical emergency. This is why, federal governments of various countries are actively involved in efforts for spreading awareness about the severity of the condition. Many government bodies are also involved in the research, development, and also the distribution of meningococcal vaccines regionally.
Transparency Market Research’s report on the global meningococcal vaccines market presents an all-inclusive overview of the market and its various segments.

The report mainly focuses on major market segments based on the types of vaccines available in the meningococcal vaccine market, such as Polysaccharide Vaccines, Conjugate Vaccines, Combination Vaccines, and the vaccines in pipeline. The product types are further segmented according to the brands that feature them. An overview of geographically specific active regional markets is also included in the report.

Conjugates are expected to lead the global meningococcal vaccines market in the future. By observing growth at a CAGR of 12.9%, this product segment could amass net worth of nearly US$2.5 billion by 2019. Amongst the various meningococcal vaccines in pipeline currently, Novartis’s Bexsero is expected to gain market shares at the fastest pace, an expected 24.7%, during the forecast period.

We are currently offering a flat 15% discount on all purchases until end of the March 2015!
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1666

The Department of Health, UK, states that Baxsero will be the first vaccine for serogroup B in the meningococcal vaccines market after its launch in the second quarter of 2014. Pfizer’s MnB rLP2086 is another potential future vaccine that is currently in its third phase of trial. The launch of this vaccine, which has received a Breakthrough Therapy status from the U.S. FDA, is expected to change the complete outlook of this market by intensifying competition.

Geographically, North America was the leading shareholder of the global meningococcal vaccines market in 2011 due to government led immunization programs and favorable research and development initiatives undertaken by major drug companies in this region. Also, every year nearly 1,000 to 2,600 people in the U.S. contract meningitis from various strains of the bacteria. However, vaccines for only the serotypes A, C, Y, and W-135 are available in the U.S. market.

Regional market of Asia Pacific is expected to grow at the fastest pace in the global meningococcal vaccines market, at an estimated CAGR of 17.1%, by the end of 2019. Major drivers of growth in these regional markets are the low manufacturing cost of vaccines, and transfer of novel manufacturing technologies from developed countries to these regions.

Download PDF: Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Browse The Market Research Blog :
https://marketsresearchindustry.wordpress.com/